RATIONALE: The Chinese herbal medicine Sho-saiko-to contains ingredients that may slow the growth of tumor cells and stimulate a person's immune system to help kill tumor cells. This may be an effective treatment following hepatic artery embolization. PURPOSE: Phase II trial to study the effectiveness of Sho-saiko-to following hepatic artery embolization in treating patients who have liver cancer.
OBJECTIVES: * Compare the overall survival of patients with unresectable hepatocellular carcinoma treated with Sho-saiko-to after ablation therapy with embolization vs historical control patients. * Compare the liver function and alpha fetoprotein levels in patients treated with this drug vs historical control patients. * Compare the intervention-free survival in patients treated with this drug vs historical control patients. OUTLINE: Beginning within 1 week after the first course of ablation therapy with embolization, patients receive oral Sho-saiko-to three times daily. Treatment with Sho-saiko-to continues in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 78 patients will be accrued for this study within 18-24 months.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.